This QI research study will encompass five phases:
Phase 1. Quality measures development & site selection.
The project's expert Advisory Committee will identify 3 - 5 quality measures related to integration of immunotherapies into practice, as well as the assessment process to quantify adherence to the measures.
Phase 2. Data collection & analysis.
In addition to data collected from the participating sites' EHRs, patient-reported data will be collected to assess variations in care related to shared decision-making.
Phase 3. Development & implementation of educational interventions & assessment tools.
Once barriers to integration of immunotherapies are identified, educational interventions will be designed to address specific challenges and to identify potential strategies to overcome these barriers. Examples of potential educational interventions include tumor boards, webinars, and additional resources/tools.
Phase 4. Repeat data collection & analysis.
Post-intervention(s) implementation, adherence to the project's quality measures will be re-assessed to determine the impact of the educational intervention(s) on integration of immunotherapies for cancer in the community setting.
Phase 5. Analyze and publish.
Findings from the study will be shared with the ACCC membership and the wider oncology community.
Presented at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium; February 6-8, 2020; Orlando, FL.
Dr. Zibelman discusses managing immune-related adverse events with OncLive:
Download IO Wallet Card